Cargando…
Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1
The autoimmune reaction against the beta cells of the pancreatic islets in type 1 diabetes mellitus (T1DM) patients is active in prediabetes and during the development of the clinical manifestation of T1DM, but it decreases within a few years of the clinical manifestation of this disease. A key role...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745590/ https://www.ncbi.nlm.nih.gov/pubmed/35008819 http://dx.doi.org/10.3390/ijms23010390 |
_version_ | 1784630382106247168 |
---|---|
author | Ben-Skowronek, Iwona Sieniawska, Joanna Pach, Emilia Wrobel, Wiktoria Skowronek, Anna Tomczyk, Zaklina Rosolowska, Iga |
author_facet | Ben-Skowronek, Iwona Sieniawska, Joanna Pach, Emilia Wrobel, Wiktoria Skowronek, Anna Tomczyk, Zaklina Rosolowska, Iga |
author_sort | Ben-Skowronek, Iwona |
collection | PubMed |
description | The autoimmune reaction against the beta cells of the pancreatic islets in type 1 diabetes mellitus (T1DM) patients is active in prediabetes and during the development of the clinical manifestation of T1DM, but it decreases within a few years of the clinical manifestation of this disease. A key role in the pathogenesis of T1DM is played by regulatory T cell (Treg) deficiency or dysfunction. Immune interventions, such as potential therapeutic applications or the induction of the Treg-cell population in T1DM, will be important in the development of new types of treatment. The aim of this study was to evaluate innovative immune interventions as treatments for T1DM. After an evaluation of full-length papers from the PubMed database from 2010 to 2021, 20 trials were included for the final analysis. The analysis led to the following conclusions: Treg cells play an important role in the limitation of the development of T1DM, the activation or application of Tregs may be more effective in the early stages of T1DM development, and the therapeutic use of Treg cells in T1DM is promising but requires long-term observation in a large group of patients. |
format | Online Article Text |
id | pubmed-8745590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87455902022-01-11 Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1 Ben-Skowronek, Iwona Sieniawska, Joanna Pach, Emilia Wrobel, Wiktoria Skowronek, Anna Tomczyk, Zaklina Rosolowska, Iga Int J Mol Sci Review The autoimmune reaction against the beta cells of the pancreatic islets in type 1 diabetes mellitus (T1DM) patients is active in prediabetes and during the development of the clinical manifestation of T1DM, but it decreases within a few years of the clinical manifestation of this disease. A key role in the pathogenesis of T1DM is played by regulatory T cell (Treg) deficiency or dysfunction. Immune interventions, such as potential therapeutic applications or the induction of the Treg-cell population in T1DM, will be important in the development of new types of treatment. The aim of this study was to evaluate innovative immune interventions as treatments for T1DM. After an evaluation of full-length papers from the PubMed database from 2010 to 2021, 20 trials were included for the final analysis. The analysis led to the following conclusions: Treg cells play an important role in the limitation of the development of T1DM, the activation or application of Tregs may be more effective in the early stages of T1DM development, and the therapeutic use of Treg cells in T1DM is promising but requires long-term observation in a large group of patients. MDPI 2021-12-30 /pmc/articles/PMC8745590/ /pubmed/35008819 http://dx.doi.org/10.3390/ijms23010390 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ben-Skowronek, Iwona Sieniawska, Joanna Pach, Emilia Wrobel, Wiktoria Skowronek, Anna Tomczyk, Zaklina Rosolowska, Iga Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1 |
title | Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1 |
title_full | Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1 |
title_fullStr | Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1 |
title_full_unstemmed | Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1 |
title_short | Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1 |
title_sort | potential therapeutic application of regulatory t cells in diabetes mellitus type 1 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745590/ https://www.ncbi.nlm.nih.gov/pubmed/35008819 http://dx.doi.org/10.3390/ijms23010390 |
work_keys_str_mv | AT benskowronekiwona potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1 AT sieniawskajoanna potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1 AT pachemilia potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1 AT wrobelwiktoria potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1 AT skowronekanna potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1 AT tomczykzaklina potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1 AT rosolowskaiga potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1 |